|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM148708080 |
| 003 |
DE-627 |
| 005 |
20250205143611.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0496.xml
|
| 035 |
|
|
|a (DE-627)NLM148708080
|
| 035 |
|
|
|a (NLM)15182450
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Xu, Xin-Nu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Anti-endotoxin core glycolipid antibody
|b the preparation of immune serum of E. Coli J5
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.11.2004
|
| 500 |
|
|
|a Date Revised 08.12.2020
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To prepare high titer anti-endotoxin core glycolipid (J5) antibody (CGL) for the treatment of Gram-negative bacteremia and septic shock
|
| 520 |
|
|
|a METHODS: Nontoxic bacterial vaccine (50 x 10(12)U/L) against E.Coli O111:B4 mutant strain J5 was prepared. J5 bacterial vaccine was injected into rabbits through ear marginal vein (saline as control preparation), one time pre three days, totally five times. Injected doses were as following: 0.1 ml, 0.2 ml, 0.4 ml, 0.6 ml, and 0.8 ml. One week after fifth injection, blood samples from heart were collected and immune serum was isolated. Indirect clotting test was used to determine the titer of antibody and cross reaction
|
| 520 |
|
|
|a RESULTS: Among 12 immunized rabbits, titers of antibody against E. Coli J5 were exceeding 1:1 024 in 6 rabbits, and they had cross reaction with various kinds of Gram-negative bacterial endotoxins
|
| 520 |
|
|
|a CONCLUSION: The titer of anti-endotoxin core glycolipid (E.Coli J5) antibody prepared by us appears to be high, and it can combine with various kinds of Gram-negative bacterial endotoxins
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Bacterial Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Endotoxins
|2 NLM
|
| 650 |
|
7 |
|a Glycolipids
|2 NLM
|
| 650 |
|
7 |
|a Immune Sera
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins
|2 NLM
|
| 650 |
|
7 |
|a antilipopolysaccharide antibodies
|2 NLM
|
| 650 |
|
7 |
|a core endotoxin
|2 NLM
|
| 700 |
1 |
|
|a Li, Zhi-Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yin-Ping
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
|d 1998
|g 16(2004), 6 vom: 07. Juni, Seite 358-60
|w (DE-627)NLM098227793
|x 1003-0603
|7 nnns
|
| 773 |
1 |
8 |
|g volume:16
|g year:2004
|g number:6
|g day:07
|g month:06
|g pages:358-60
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 16
|j 2004
|e 6
|b 07
|c 06
|h 358-60
|